Pharmacokinetics of High-dose Melphalan in Children and Adults

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 1986 Jan 1

PMID 3948304

Citations 27

Authors

A Gouyette

O Hartmann

J L Pico

Affiliations

Soon will be listed here.

Abstract

Melphalan pharmacokinetics were studied in 20 children with stage IV neuroblastomas or Ewing's sarcomas and in 10 adults with AML, ALL, or small cell lung carcinomas, after IV administration of high doses (140 mg/m2 with furosemide-induced diuresis and 180 mg/m2 without induced diuresis) and high fluid intake (3000 ml/m2/day). Unchanged melphalan was assayed in plasma and cerebrospinal fluid by means of a high-performance liquid chromatographic procedure. The elimination half-life (t1/2 less than 80 min) allows autologous bone marrow transplantation 24 h after the drug administration. In some children we were able to detect melphalan in cerebrospinal fluid samples.

Citing Articles

Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures.

Diamond B, Ziccheddu B, Maclachlan K, Taylor J, Boyle E, Arango Ossa J Blood. 2023; 141(19):2359-2371.

PMID: 36626250 PMC: 10273163. DOI: 10.1182/blood.2022018244.

Determination of melphalan in human plasma by UPLC-UV method.

Huang L, Cheah V, Chan D, Marzan F, Dvorak C, Aweeka F Cancer Chemother Pharmacol. 2019; 83(5):905-910.

PMID: 30847504 PMC: 6490959. DOI: 10.1007/s00280-019-03786-6.

Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis.

Lee S, Meehan R, Seldin D, Sloan J, Quillen K, Shelton A Bone Marrow Transplant. 2016; 51(10):1318-1322.

PMID: 27183092 DOI: 10.1038/bmt.2016.132.

A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma.

Villablanca J, Volchenboum S, Cho H, Kang M, Cohn S, Anderson C Pediatr Blood Cancer. 2016; 63(8):1349-56.

PMID: 27092812 PMC: 8992729. DOI: 10.1002/pbc.25994.

A case of melphalan sustained accumulation in an 80-year old patient.

Jolivot P, Poinsignon V, Paci A, Guidet B, Pichereau C, Fernandez C Int J Clin Pharm. 2015; 37(6):984-7.

PMID: 26394785 DOI: 10.1007/s11096-015-0197-x.

References

Davis T, Peng Y, Goodman G, Alberts D . HPLC, MS, and pharmacokinetics of melphalan, bisantrene and 13-cis retinoic acid. J Chromatogr Sci. 1982; 20(11):511-6. DOI: 10.1093/chromsci/20.11.511. View

DArgenio D, Schumitzky A . A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed. 1979; 9(2):115-34. DOI: 10.1016/0010-468x(79)90025-4. View

Pallante S, Fenselau C, Mennel R, Brundrett R, Appler M, Rosenshein N . Quantitation by gas chromatography-chemical ionization-mass spectrometry of phenylalanine mustard in plasma of patients. Cancer Res. 1980; 40(7):2268-72. View

Hedley D, McElwain T, Millar J, Gordon M . Acceleration of bone-marrow recovery by pre-treatment with cyclophosphamide in patients receiving high-dose melphalan. Lancet. 1978; 2(8097):966-8. DOI: 10.1016/s0140-6736(78)92529-1. View

Bosanquet A, Gilby E . Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. Eur J Cancer Clin Oncol. 1982; 18(4):355-62. DOI: 10.1016/0277-5379(82)90006-2. View

Gouyette A . Pharmacokinetics: statistical moment calculations. Arzneimittelforschung. 1983; 33(1):173-6. View

Furner R, MELLETT L, Brown R, Duncan G . A method for the measurement of L-phenylalanine mustard in the mouse and dog by high-pressure liquid chromatography. Drug Metab Dispos. 1976; 4(6):577-83. View

Alberts D, Chang S, Chen H, MOON T, Evans T, Furner R . Kinetics of intravenous melphalan. Clin Pharmacol Ther. 1979; 26(1):73-80. DOI: 10.1002/cpt197926173. View

Chang S, Alberts D, Melnick L, Walson P, Salmon S . High-pressure liquid chromatographic analysis of melphalan in plasma. J Pharm Sci. 1978; 67(5):679-82. DOI: 10.1002/jps.2600670529. View

10.

Chang S, Alberts D, Farquhar D, Melnick L, Walson P, Salmon S . Hydrolysis and protein binding of melphalan. J Pharm Sci. 1978; 67(5):682-4. DOI: 10.1002/jps.2600670530. View

11.

McElwain T, Hedley D, Gordon M, Jarman M, Millar J, Pritchard J . High dose melphalan and non-cryopreserved autologous bone marrow treatment of malignant melanoma and neuroblastoma. Exp Hematol. 1979; 7 Suppl 5:360-71. View

12.

Smith J, Rutledge F . Advances in chemotherapy for gynecologic cancer. Cancer. 1975; 36(2):669-74. DOI: 10.1002/1097-0142(197508)36:2+<669::aid-cncr2820360809>3.0.co;2-a. View

13.

Lazarus H, Herzig R, Wolff S, Phillips G, Strandjord S, Hurd D . Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol. 1983; 1(6):359-67. DOI: 10.1200/JCO.1983.1.6.359. View

14.

Tattersall M, Jarman M, Newlands E, Holyhead L, Milstead R, Weinberg A . Pharmaco-kinetics of melphalan following oral or intravenous administration in patients with malignant disease. Eur J Cancer (1965). 1978; 14(5):507-13. DOI: 10.1016/0014-2964(78)90253-0. View

15.

Alexanian R, BERGSAGEL D, MIGLIORE P, Vaughn W, Howe C . Melphalan therapy for plasma cell myeloma. Blood. 1968; 31(1):1-10. View

16.

Taha I, Ahmad R, Rogers D, Pritchard J, Rogers H . Pharmacokinetics of melphalan in children following high-dose intravenous injection. Cancer Chemother Pharmacol. 1983; 10(3):212-6. DOI: 10.1007/BF00255766. View

17.

Niskanen E . Preservation of human granulopoietic precursors following storage in the nonfrozen state. Transplantation. 1983; 36(3):341-3. DOI: 10.1097/00007890-198309000-00024. View